Cargando…
An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system
A cDNA comprising the complete genome of West Nile Virus (WNV) was generated by chemical synthesis using published sequence data, independent of any preformed viral components. The synthetic WNV, produced by transfection of in vitro transcribed RNA into cell culture, exhibited undistinguishable biol...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115638/ https://www.ncbi.nlm.nih.gov/pubmed/20211218 http://dx.doi.org/10.1016/j.vaccine.2010.02.092 |
_version_ | 1783514140445245440 |
---|---|
author | Orlinger, Klaus K. Holzer, Georg W. Schwaiger, Julia Mayrhofer, Josef Schmid, Karl Kistner, Otfried Noel Barrett, P. Falkner, Falko G. |
author_facet | Orlinger, Klaus K. Holzer, Georg W. Schwaiger, Julia Mayrhofer, Josef Schmid, Karl Kistner, Otfried Noel Barrett, P. Falkner, Falko G. |
author_sort | Orlinger, Klaus K. |
collection | PubMed |
description | A cDNA comprising the complete genome of West Nile Virus (WNV) was generated by chemical synthesis using published sequence data, independent of any preformed viral components. The synthetic WNV, produced by transfection of in vitro transcribed RNA into cell culture, exhibited undistinguishable biological properties compared to the corresponding animal-derived wild-type virus. No differences were found concerning viral growth in mammalian and insect cell lines and concerning expression of viral proteins in cells. There were also no significant differences in virulence in mice following intranasal challenge. After immunizations of mice with experimental vaccines derived from the synthetic and wild-type viruses, protection from lethal challenge was achieved with similar amounts of antigen. Both vaccine preparations also induced comparable levels of neutralizing antibodies in mice. In addition, the synthetic approach turned out to be very accurate, since the rescued WNV genome contained no undesired mutations. Thus, the first flavivirus based on chemical gene synthesis was indistinguishable from the parent virus. This demonstrates that virus isolates from animal sources are dispensable to derive seed viruses for vaccine production or research. |
format | Online Article Text |
id | pubmed-7115638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71156382020-04-02 An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system Orlinger, Klaus K. Holzer, Georg W. Schwaiger, Julia Mayrhofer, Josef Schmid, Karl Kistner, Otfried Noel Barrett, P. Falkner, Falko G. Vaccine Article A cDNA comprising the complete genome of West Nile Virus (WNV) was generated by chemical synthesis using published sequence data, independent of any preformed viral components. The synthetic WNV, produced by transfection of in vitro transcribed RNA into cell culture, exhibited undistinguishable biological properties compared to the corresponding animal-derived wild-type virus. No differences were found concerning viral growth in mammalian and insect cell lines and concerning expression of viral proteins in cells. There were also no significant differences in virulence in mice following intranasal challenge. After immunizations of mice with experimental vaccines derived from the synthetic and wild-type viruses, protection from lethal challenge was achieved with similar amounts of antigen. Both vaccine preparations also induced comparable levels of neutralizing antibodies in mice. In addition, the synthetic approach turned out to be very accurate, since the rescued WNV genome contained no undesired mutations. Thus, the first flavivirus based on chemical gene synthesis was indistinguishable from the parent virus. This demonstrates that virus isolates from animal sources are dispensable to derive seed viruses for vaccine production or research. Elsevier Ltd. 2010-04-26 2010-03-06 /pmc/articles/PMC7115638/ /pubmed/20211218 http://dx.doi.org/10.1016/j.vaccine.2010.02.092 Text en Copyright © 2010 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Orlinger, Klaus K. Holzer, Georg W. Schwaiger, Julia Mayrhofer, Josef Schmid, Karl Kistner, Otfried Noel Barrett, P. Falkner, Falko G. An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system |
title | An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system |
title_full | An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system |
title_fullStr | An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system |
title_full_unstemmed | An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system |
title_short | An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system |
title_sort | inactivated west nile virus vaccine derived from a chemically synthesized cdna system |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115638/ https://www.ncbi.nlm.nih.gov/pubmed/20211218 http://dx.doi.org/10.1016/j.vaccine.2010.02.092 |
work_keys_str_mv | AT orlingerklausk aninactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT holzergeorgw aninactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT schwaigerjulia aninactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT mayrhoferjosef aninactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT schmidkarl aninactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT kistnerotfried aninactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT noelbarrettp aninactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT falknerfalkog aninactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT orlingerklausk inactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT holzergeorgw inactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT schwaigerjulia inactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT mayrhoferjosef inactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT schmidkarl inactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT kistnerotfried inactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT noelbarrettp inactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem AT falknerfalkog inactivatedwestnilevirusvaccinederivedfromachemicallysynthesizedcdnasystem |